Previous Article | Next Article 
Infection and Immunity, June 2001, p. 3685-3691, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3685-3691.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Complement Evasion by Borrelia
burgdorferi: Serum-Resistant Strains Promote C3b
Inactivation
Antti
Alitalo,1
Taru
Meri,1
Lasse
Rämö,1
T. Sakari
Jokiranta,1
Tero
Heikkilä,1
Ilkka J. T.
Seppälä,1
Jarmo
Oksi,2
Matti
Viljanen,3 and
Seppo
Meri1,*
Department of Bacteriology and Immunology,
Haartman Institute and HUCH Laboratory Diagnostics, FIN-00014
University of Helsinki, Helsinki,1 and
Departments of Internal Medicine and Medical Microbiology,
University of Turku,2 and National
Public Health Institute, Department in Turku, and Turku Immunology
Center,3 Turku, Finland
Received 21 July 2000/Returned for modification 12 September
2000/Accepted 26 February 2001
 |
ABSTRACT |
The most characteristic features of the Lyme disease pathogens, the
Borrelia burgdorferi sensu lato (s.l.) group, are their ability to invade tissues and to circumvent the immune defenses of the
host for extended periods of time, despite elevated levels of
borrelia-specific antibodies in serum and other body fluids. Our aim in
the present study was to determine whether B.
burgdorferi is able to interfere with complement (C) at the
level of C3 by accelerating C3b inactivation and thus to inhibit the
amplification of the C cascade. Strains belonging to different
genospecies (Borrelia garinii, B.
burgdorferi sensu stricto, and Borrelia afzelii)
were compared for their sensitivities to normal human serum and
abilities to promote factor I-mediated C3b degradation. B.
burgdorferi sensu stricto and B. afzelii strains
were found to be serum resistant. When the spirochetes were incubated
with radiolabeled C3b, factor I-mediated degradation of C3b was
observed in the presence of C-resistant B. afzelii
(n = 3) and B. burgdorferi sensu
stricto (n = 1) strains but not in the presence of
C-sensitive B. garinii (n = 7)
strains or control bacteria (Escherichia coli,
Staphylococcus aureus, and Enterococcus
faecalis). Immunoblotting and radioligand binding analyses
showed that the C-resistant strains had the capacity to acquire the C
inhibitors factor H and factor H-like protein 1 (FHL-1) from growth
medium and human serum. A novel surface protein with an apparent
molecular mass of 35 kDa was found to preferentially bind to the N
terminus region of factor H. Thus, the serum-resistant B.
burgdorferi s.l. strains can circumvent C attack by binding the
C inhibitors factor H and FHL-1 to their surfaces and promoting factor
I-mediated C3b degradation.
 |
INTRODUCTION |
The Borrelia
burgdorferi sensu lato (s.l.) group of spirochetes are the
causative agents of Lyme disease, a vector-borne illness with a
widespread distribution in the Northern hemisphere. Lyme disease occurs
at least in Europe, North America, and Asia and is transmitted by
locally occurring ticks of the Ixodes ricinus complex
(29). Progression of the infection can be divided into localized (I), disseminated (II), and persistent (III) stages (28), where patients at the localized stage usually
present with erythema migrans and fever. The second stage of infection has more-variable clinical manifestations, with specific organs being infected. Disorders of the central nervous system, heart, liver,
spleen, and eye have all been described in conjunction with
disseminated Lyme borreliosis. In the third stage, nonpurulent arthritis is the most common manifestation but other immunological phenomena and acrodermatitis chronica atrophicans are occasionally observed. Three genospecies of the B. burgdorferi s.l. group
have been identified (3). They seem to prefer different
organs and, thus, cause different clinical manifestations in the
disseminated and persistent stages. Borrelia garinii is
often associated with neuroborreliosis, and B. burgdorferi
sensu stricto (s.s.) is often associated with arthritis, whereas
Borrelia afzelii seems to cause acrodermatitis chronica
atrophicans more often than the other genospecies (1, 2,
32). Overall, the Lyme disease spirochetes are characterized by
their ability to invade tissues and evade host immune defenses for
extended periods of time despite the appearance of antibodies in serum
and other body fluids.
The complement system is one of the most versatile parts of the immune
system. In general, most microbes activate the complement system, which
eventually leads to phagocytosis of the target and/or formation of the
membrane attack complexes (MAC). The MAC can usually be effectively
assembled only on the surfaces of gram-negative bacteria that have an
outer cell membrane. In both the classical and the alternative pathways
the most central step in complement activation is generation of C3b.
C3b is a ligand for immune adhesion and immune complex clearance as
well as a subunit in the alternative-pathway C3/C5 convertase, C3bBb,
and in the classical-pathway C5 convertase, C4b2a3b. Considerable
amplification of the complement cascade occurs at the C3 level by
cleavage of C3 to C3b by C3bBb. The newly formed C3b binds factor B. C3bBb generated after cleavage of B to Bb makes this step a
self-amplifying process that leads to efficient C3b opsonization. In
addition, by converting C5 into C5b the C5 convertases start the
downstream cascade that leads to MAC formation and lysis of susceptible cells.
Considering the characteristic features of B. burgdorferi
infection it is obvious that the B. burgdorferi s.l.
spirochetes must somehow avoid complement attack. In the tick gut the
spirochetes may be protected by complement-inhibiting factors in tick
saliva, which prevent C3b deposition on complement-activating surfaces (25). However, upon invasion of subcutaneous tissues and
in disseminated infection Borrelia spirochetes must have
other means of avoiding the complement system. Several microbes are
known to interfere with complement at the C3b level, for example, by accelerating decay of the C3 convertase enzymes (Trypanosoma
cruzi) (31), by promoting C3b inactivation (vaccinia
virus complement control protein, VCP, or herpes simplex virus type 1)
(14, 15, 17), or by binding host complement regulators
onto their own cell surfaces (e.g., Streptococcus pyogenes
binding host factor H [8]). Host cells protect
themselves from complement-mediated destruction with the help of
membrane regulators complement receptor type 1 (CR1; CD35),
membrane cofactor protein (MCP; CD46), and decay accelerating factor
(DAF; CD55) (19) and by binding plasma protein factor H or
factor H-like protein 1 (FHL-1) to their membranes (18).
Factor H is the most important soluble regulator of the alternative
pathway. It can (i) act as a cofactor for serine protease factor I in
C3b inactivation, (ii) replace Bb from the C3bBb convertase, and (iii)
compete with factor B for binding to C3b. In performing these functions
factor H uses as many as three distinct binding sites for C3b
(10, 27) and several binding sites for glycosaminoglycans and/or sialic acids. Multiple interactions between surface-bound C3b
and factor H are needed for discrimination between alternative-pathway activators (e.g., microbes) and nonactivators (host cells).
In an earlier study it was observed that B. garinii strains
are sensitive to the bactericidal activity of serum (i.e., complement sensitive), whereas the B. burgdorferi s.s. strains are only
partially sensitive and the B. afzelii strains are resistant
(4). These findings are correlated with the susceptibility
of these strains to complement-dependent phagocytosis in human serum
(30). Our aim in this study was to determine whether
bacterial control of the alternative complement pathway might
contribute to the pathogenicity of B. burgdorferi s.l. To
this end we analyzed the complement sensitivities of different
genospecies of B. burgdorferi s.l. and their effects on C3b
degradation in vitro. We observed that B. afzelii and
B. burgdorferi s.s. strains, which were complement resistant
in a serum immobilization assay, promoted factor I-mediated inactivation of C3b while the serum-sensitive B. garinii
strains did not. The underlying mechanism was revealed when we observed that the complement-resistant Borrelia strains had acquired
complement inhibitors factor H and FHL-1 from serum containing growth
media. B. burgdorferi s.s. and B. afzelii bound
these soluble complement inhibitors from serum by a surface protein
with a molecular mass of 35 kDa. Acceleration of C3b inactivation by
acquisition of soluble complement regulators factor H and FHL-1 is thus
probably an important immune evasion mechanism of serum-resistant
strains of B. burgdorferi.
 |
MATERIALS AND METHODS |
Spirochetal strains.
Eleven low-passage (n < 15) B. burgdorferi s.l. strains were used in this study.
All strains were obtained from The National Public Health Institute,
Department in Turku (NPHI). B. burgdorferi s.s. strain ia
was isolated by the NPHI from one of the first culture-confirmed Lyme
disease patients in Finland (M. K. Viljanen, J. Oksi, P. Salomaa,
M. Skurnik, R. Peltonen, and H. Kalimo, Letter, J. Infect. Dis.
165:596-597, 1992). Three B. afzelii strains (A91, 570, and 1082) were used. A91 and 1082 were patient isolates from
Turku, Finland, and 570 was isolated from a tick caught in Helsinki in
1996. The B. garinii strains (3/96, 5/96, 13/96, 28/97, 40/97, 46/97, and 50/97) were isolated in 1996 and 1997 from erythema migrans lesions of patients in the archipelago of Turunmaa close to Turku.
Spirochetes were cultured in BSK-H medium (Sigma Chemicals, St. Louis,
Mo.) at 33°C in a 5% CO2 atmosphere. The
medium contained 6% heat-inactivated rabbit serum. Growth was
maintained for 2 weeks or until the culture had reached a density of at
least 107 bacteria/ml, as calculated by
dark-field microscopy. The bacteria were centrifuged (8,000 × g) and washed extensively with Veronal-buffered saline
(VBS), pH 7.4. The final concentration was adjusted to 109 bacteria/ml.
Serum sensitivity test.
Borrelia bacteria were
cultured until a density of at least 107/ml was
reached. The concentration of bacteria was estimated by counting 10 microscope fields at ×40 magnification. Serum from a healthy
laboratory worker without B. burgdorferi antibodies was
extracted by drawing blood and letting it stand for 30 min at room
temperature. Subsequently the blood was centrifuged and the serum was
aliquoted and frozen (
70°C). For the serum sensitivity test the
reaction mixtures were pipetted to a volume of 100 µl. Bacteria (50 µl/reaction mixture) were centrifuged (6,000 × g) and washed three times with BSK-II buffer. Four different reaction mixtures were set up for each strain: 10, 20, and 40% normal human serum (NHS) and heat-inactivated serum. Serum was diluted with the BSK-II medium. The mixtures were incubated at 37°C for a total of
16 h, and 10-µl aliquots were removed for analysis at 2, 5, and
16 h. The aliquots were pipetted onto microscope slides and analyzed using an Olympus microscope with dark field. The number of
bacteria and the percentages of live bacteria were estimated and
categorized into one of the following groups: 100, 75, 25, 5, or 0%
live bacteria at each time point. The strains were classified as either
sensitive or resistant based on the end point category at 16 h
(Fig. 1).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Analysis of serum resistance of B.
burgdorferi s.l. strains. The indicated strains were incubated
in nonimmune human serum at 37°C for 16 h. The survival of
bacteria at specified time points was calculated as the percentage of
motile, live bacteria by dark-field microscopy. The different B.
burgdorferi strains fell into two distinct categories. While
the B. burgdorferi s.s. and B. afzelii
strains were resistant to serum killing, all the tested B.
garinii strains were classified as serum sensitive.
|
|
Complement components.
Factor I used in the experiments was
either supplied by Calbiochem-Novabiochem (La Jolla, Calif.) or
purified from human plasma as described previously (13).
Factor H and C3 were purified from human plasma (18), and
C3b was generated from C3 with factors B and D in the presence of
Ni2+ ions as described previously (12,
13). Recombinant FHL-1 was kindly provided by Jens Hellwage and
Peter Zipfel (6). C4b was purchased from Quidel Corp. (La
Jolla, Calif.), and C4bp was provided by Anna Blom (University of Lund,
Lund, Sweden). C3b, C4b, factor H, and FHL-1 were radiolabeled with
125I using the Iodogen method (26)
(Pierce Chemical Group, Rockford, Ill.).
Factor I cofactor assay.
In the optimized factor I cofactor
assay the bacteria (approximately 4 × 107)
were incubated with factor I (500 ng) and radiolabeled C3b (50,000 cpm)
at 37°C for 1.5 h in 40 µl of VBS containing 0.1% gelatin. Gelatin was present in the reaction mixture to prevent adhesion of the
reactants to surfaces of the reaction tube. After incubation the
samples were run on sodium dodecyl sulfate-8% polyacrylamide gel
electrophoresis (SDS-8% PAGE) gels under reducing conditions. The gel was fixed in 5% acetic acid for 30 min, dried, and
autoradiographed using the Fujifilm BAS 2500 instrument (Fuji Photo
Film, Tokyo, Japan).
In controls, the C3b degradation assay was carried out in the absence
of
Borrelia bacteria or in the presence of selected
strains
of
Escherichia coli,
Staphylococcus aureus, and
Enterococcus faecalis instead of
B. burgdorferi.
The control bacteria were
isolated at the Helsinki University Central
Hospital diagnostics
laboratory and were selected randomly for the
assay. The positive
control mixture consisted of factor H (5 or 0.5 µg/ml), factor
I, and
125I-C3b. In addition, a
sample of
125I-C3b or
125I-C4b without factors I and H was used
to monitor for any spontaneous
degradation under the experimental
conditions.
Immunoblotting analysis of factor H binding.
Factor H
binding by the strains used in the cofactor assay was analyzed by an
immunoblotting assay. Two different preparations of B. afzelii A91, two B. garinii strains (3/96 and 46/97),
and B. burgdorferi s.s. ia that had been grown in the BSK-H
medium and washed three times with VBS were mixed with a reducing
SDS-PAGE sample buffer. The samples containing
107 bacteria/ml were incubated at 37°C for 20 min on a shaker, and aliquots were run on an SDS-8% PAGE gel. The
samples were electrotransferred onto a nitrocellulose membrane, and the
membrane was blocked with 5% fat-free milk in phosphate-buffered
saline (PBS). Polyclonal goat anti-factor H antibody (1:5,000 dilution)
was added, and the membrane was incubated for 12 h at 4°C. The
membrane was washed five times, and a secondary peroxidase-conjugated
donkey anti-goat antibody (diluted 1:5,000 in 1% bovine serum
albumin-PBS) was added and incubated with the membrane for 60 min at
room temperature on a shaker. The membrane was washed with PBS, and
positive reactions were visualized by the electrochemiluminescence
method (Amersham, Little Chalfont, United Kingdom).
Analysis of factor H and FHL-1 binding by ligand blotting.
Outer membranes (OM) and protoplasmic cylinders (PC) of one strain of
each genospecies of Borrelia bacteria were isolated using a
method described previously (21). The OM and PC specimens were run on an SDS-8% PAGE gel under nonreducing conditions and transferred onto a nitrocellulose membrane. The membranes were blocked
with 5% fat-free milk in PBS for 60 min at room temperature. 125I-labeled factor H and FHL-1
(106 cpm/membrane) were incubated on the
membranes for 24 h at 4°C on a shaker. The membranes were washed
five times with PBS and analyzed by autoradiography.
 |
RESULTS |
Serum sensitivity testing of Borrelia species.
The serum sensitivities of various strains of B. burgdorferi
were tested by incubating (37°C) the bacteria in 10, 20, and 40% NHS
for 16 h. Samples from the reaction mixtures were taken at 2, 5, and 16 h for microscopy, and the percentages of live bacteria were
estimated. B. burgdorferi s.s. ia, B. afzelii
1082, and B. afzelii A91 were classified as resistant, and
B. garinii 3/96, 5/96, and 46/97 were classified as
sensitive, at the 16-h endpoint (Fig. 1).
With regard to the differences in serum sensitivity we next compared
the promotion of C3b cleavage by the various
Borrelia genospecies. When
125I-C3b was incubated for
1.5 h at 37°C with
B. afzelii (A91) and
factor I, a
distinct C3b degradation pattern was observed (Fig.
2). The

' chain of C3b became cleaved
into 68-, 46-, and 43-kDa
fragments. The amount of cleavage product
increased with an increasing
concentration of bacteria (Fig.
2),
and the pattern of cleavage
resembled that obtained with factors H and
I. In the absence of
factor I or bacteria, no cleavage of C3b took
place. As controls
we tested other bacteria that had been isolated at
our diagnostics
laboratory. Neither
E. faecalis
(
n = 1),
S. aureus (
n = 1),
nor
E. coli (
n = 1) exhibited C3b-degrading
activity in the presence
or absence of factor I (not shown).

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 2.
SDS-PAGE and autoradiography analysis of C3b cleavage by
B. afzelii strain A91. Various amounts of bacteria
(lanes 3 to 5 [numbering from the left]: 109,
108, and 107/ml, respectively) grown in
BSK-H medium were incubated in a final volume of 40 µl for 1.5 h
at 37°C with radiolabeled C3b (1.25 µg/ml; 106
cpm/µg) in the presence of factor I (12.5 µg/ml). Lane 1, negative
control with 125I-C3b plus I; lane 2, positive control
(125I-C3b, factor I, and 0.5 µg of factor H/ml). Note the
cleavage of the ' chain of C3b into fragments representing those of
iC3B (lane 3). The image was produced using the Fujifilm BAS
2500 instrumentation and MacBAS, version 2.5, and Adobe Photoshop,
version 5.5, software.
|
|
When a larger panel of
Borrelia strains was tested, it was
observed that
B. burgdorferi s.s. (ia) and
B. afzelii strains (A91,
570, and 1082) promoted cleavage of C3b in
the cofactor assay,
whereas the seven strains of
B. garinii
(strains 3/96, 5/96, 13/96,
28/97, 40/97, 46/97, and 50/97) did not
(Fig.
3 and
4). A similar
cleavage pattern was
observed with all
B. afzelii strains (Fig.
4). The cleavage
pattern obtained with
B. burgdorferi s.s. was
somewhat
different from that obtained with the
B. afzelii strains.
Incubation of the
B. burgdorferi s.s. ia strain with
125I-C3b and factor I produced a fourth

'-chain 41-kDa band in addition
to the 68-, 46-, and 43-kDa bands.
This cleavage pattern possibly
indicated a more efficient C3b
inactivation by
B. burgdorferi s.s. than by
B. afzelii. No cleavage occurred with either
B. burgdorferi s.s. or
B. afzelii in the absence of factor
I, indicating that
the cleavage was not due to a protease on the
borrelial surface.
The concentration of bacteria that induced C3b
cleavage was about
10
8 bacteria/ml, and the
concentration of factor H used in controls
was approximately 5 µg/ml.
At the latter concentration factor
H with I produced almost complete
cleavage of
125I-C3b (50,000 cpm) during the
1.5-h incubation period.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of levels of C3b cleavage by factor I (12.5 µg/ml) in the presence of the three genospecies of B.
burgdorferi s.l. grown in BSK-H medium. The C3b
inactivation-promoting activity for factor I was tested with
approximately 109 bacteria/ml. Lanes 1 and 2 (numbering
from the left), cleavage of C3b produced by B.
burgdorferi (B. b.) s.s. ia and B.
afzelii A91, respectively. Under the conditions used, the
cleavage of 125I-C3b progressed to a different degree in
the presence of factor H (lane 10; 5 µg/ml) and the two strains.
Unlike the other strains tested, none of the B. garinii
strains (3/96, 5/96, 13/96, 28/97, 40/97, 46/97, and 50/97) promoted
125I-C3b cleavage. The image was produced as in Fig. 2.
|
|

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of 125I-C3b cleavage by three
B. afzelii strains grown in BSK-H. All three strains
(A91, 570, and 1082) yielded weak but similar C3b cleavage patterns
with factor I (12.5 µg/ml). No cleavage of C3b with B.
garinii was observed. The positive control shows
125I-C3b cleavage with factors H (5 µg/ml) and I. The
image was produced as in Fig. 2.
|
|
Acquisition of factor H and FHL-1 from growth medium by
Borrelia.
In order to determine the factor
responsible for the observed cofactor activity, we tested for the
possibility that the bacteria had acquired factor H from their growth
media. The presence of factor H was analyzed by immunoblotting using a
goat antibody that recognizes both human and rabbit factor H. Two
different preparations of B. afzelii A91, two B. garinii strains (3/96 and 46/97), and B. burgdorferi
s.s. ia that had been grown in the BSK-H medium were washed and
incubated in SDS-PAGE sample buffer and run on an SDS-PAGE gel.
Immunoblotting with the polyclonal anti-factor H antibody revealed
factor H on the surfaces of B. afzelii A91 and B. burgdorferi s.s. ia strains (Fig.
5). In addition, B. burgdorferi s.s. ia appeared to have bound a
lower-molecular-weight protein that corresponded to FHL-1, an
alternatively spliced 43-kDa product of the factor H gene. No bound
factor H or the putative FHL-1 on either of the B. garinii
strains was observed.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 5.
Uptake of complement factor H and FHL-1 from the growth
medium by the different B. burgdorferi strains. Two
batches of B. afzelii A91, two strains of B.
garinii, and B. burgdorferi s.s. strain ia were
grown in BSK-H medium. After being washed three times with VBS the
bacterial preparations were run on SDS-PAGE gel and immunoblotted on
nitrocellulose with a polyclonal anti-factor H antibody. Purified
factor H (1.0 and 0.1 ng on lanes 6 and 7 [lanes are numbered from the
left], respectively) and NHS (lane 8) were run as positive controls.
Uptake of 150-kDa factor H occurred with the B. afzelii
and B. burgdorferi s.s. strains but not with the
B. garinii strains. In addition, B.
burgdorferi s.s. bound a protein that corresponds to FHL-1.
FHL-1 can be separated from the comigrating FHR-1 because FHL-1 runs
as a single band at 43 kDa (lane 5) and FHR-1 runs as a doublet at 43 (FHR-1 ) and 37 kDa (FHR-1 ; lane 8).
|
|
Binding of factor H and FHL-1 to borrelial surface proteins.
B. burgdorferi s.l. has a two-layer OM with very few
proteins on the outermost membrane. In order to localize the factor H binding molecule(s), OM of strains of all three genospecies were isolated by ultracentrifugation through sucrose density gradient columns. OM and PC were collected, run on SDS-PAGE gels, and
transferred onto nitrocellulose membranes. Factor H and FHL-1 binding
to the OM and PC of the strains representing all three genospecies was analyzed by incubating the membranes with radiolabeled factor H (Fig.
6, top) and FHL-1 (Fig. 6, bottom).
Factor H binding to B. burgdorferi s.s. ia OM and PC
fractions was observed, suggesting that a factor H binding molecule is
present on the OM. The factor H binding protein had an approximate
molecular mass of 35 kDa. This protein was distinct from 19-kDa outer
surface protein OspE, which in a separate study (7) was
identified as a factor H ligand. FHL-1 binding to the 35-kDa protein on
B. afzelii A91 OM and PC fractions as well as on the
B. burgdorferi s.s. PC fraction was observed. This suggests
that a molecule binding FHL-1 can be found on the OM of at least the
B. afzelii strains. No binding of either factor H or FHL-1
to B. garinii proteins was observed. Also, no binding of
125I-labeled C4bp to Borrelia bacteria
was observed. The results therefore suggest that factor H and FHL-1
selectively bind to the OM of both B. burgdorferi s.s. and
B. afzelii strains. This tentatively accounts for the
observed differences in serum sensitivity and C3b degradation-promoting
activity.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 6.
Ligand blotting analysis of 125I-factor H
and 125I-FHL-1 binding to B. burgdorferi
s.l. strains. OM and PC of three strains representing all three
genospecies were isolated using ultracentrifugation through sucrose
gradients. OM and PC were run on a nonreducing SDS-PAGE gel and
electrotransferred onto a nitrocellulose membrane. Factor H binding
protein OspE (19 kDa) and a factor H antibody were run as positive
controls. The samples were probed with radiolabeled factor H (top) and
FHL-1 (bottom). B. burgdorferi (B.
b.) s.s. was observed to bind both factor H and FHL-1,
whereas B. afzelii A91 bound preferentially FHL-1 and
B. garinii bound neither. Factor H and FHL-1 bound to a
protein with an approximate molecular mass of 35 kDa which is distinct
from the 19-kDa OspE protein.
|
|
 |
DISCUSSION |
In this study we observed that the complement-resistant B. burgdorferi s.s. and B. afzelii strains can promote C3b
inactivation and thereby escape complement attack, whereas the B. garinii strains did not have this activity. The C3b
cleavage-promoting activity of the B. burgdorferi s.s. and
B. afzelii genospecies was associated with the ability of
these strains to bind the soluble complement inhibitors factor H and
FHL-1. B. garinii strains did not bind either factor. This
suggests that the ability to bind factor H or FHL-1 is protective for
the bacteria in serum in vitro and presumably also in the mammalian
host and possibly in the tick. The acquisition of factor H from the
rabbit serum containing growth medium explains why in vitro-cultivated
bacteria had C3b cleavage-promoting activity.
To confirm the localization of the factor H and FHL-1 binding
molecule, we isolated OM of three strains representing all three genospecies of B. burgdorferi s.l. Factor H binding to
B. burgdorferi s.s. OM could be confirmed as well as the
binding of FHL-1 to the OM of B. afzelii. The target
molecule for factor H and FHL-1 had an approximate molecular mass of 35 kDa. In a separate study (7) factor H was observed to bind
to the 19-kDa OspE outer surface protein of B. burgdorferi
s.s. via its C terminus. This, together with the fact that FHL-1, an
N-terminally truncated form of factor H, preferentially bound to
B. afzelii and recognized a 35-kDa protein, suggests that
there are two separate mechanisms for binding factor H and FHL-1 to
complement-resistant strains of Borrelia. Apparently,
these mechanisms protect the OM of the bacteria against complement
attack in the mammalian host. As such the binding of factor H and FHL-1
represents a novel virulence mechanism of B. burgdorferi
s.s. and B. afzelii strains.
The binding of factor H and FHL-1 as a virulence mechanism has been
reported previously for other bacteria. For example, the M protein of
group A streptococci (8) and Hic of pneumococci (9) have been shown to function as factor H binding
proteins. By binding factor H or FHL-1 to their surfaces the bacteria
can protect themselves by promoting factor I-mediated degradation of
C3b. In Neisseria gonorrhoeae a somewhat similar protection mechanism has been described; the sialylated surface
lipooligosaccharide or the porin 1A protein binds factor H thus
protecting the bacteria against complement attack (22,
23). The binding of factor H and FHL-1 thus represents an
important complement resistance mechanism, which is shared by a growing
number of microbes.
Bacteria and viruses use different kinds of mechanisms of
complement evasion (24). While bacteria mostly seem to
bind host complement regulators, viruses utilize endogenous promoters
for C3b cleavage. The VCP protein of vaccinia virus acts as a cofactor in C3b degradation (15). This protein contains short
consensus repeat (SCR) domains, which are typical structural subunits
of mammalian complement regulators, such as factor H, CD46, and CD35. Genes for similar factors have tentatively been identified in the
highly pathogenic monkeypox and smallpox viruses (14;
S. N. Shchelkunov, A. V. Totmenin, P. F. Safronov,
O. I. Ryazankina, V. V. Gutorov, and N. A. Petrov,
Abstract, Immunologist 6:412, 1998). Herpes simplex virus
type 1 has a protein (gC-1) that lacks SCR domains but that binds to
C3b and exhibits decay-accelerating activity for the C3bBb convertase
(16). T. cruzi possesses a DAF-like protein,
T-DAF, which seems to be crucial in protecting this protozoan parasite
against complement attack (31). The facts that the protein
synthesis machinery of bacteria is not very good in making proteins
with disulfide bonds and that no proteins with significant homology to
factor H or MCP/CD46 are present in the borrelial genome
(5) suggest that the Borrelia bacteria do not
have intrinsic cofactors with an SCR structure.
In our serum sensitivity test, we observed that the B. burgdorferi s.s. and B. afzelii strains were resistant
to serum immobilization and vacuolization, whereas all the B. garinii strains were sensitive to these effects of serum. Earlier,
Breitner-Ruddock and colleagues observed in their study
(4) that B. garinii strains activated the
alternative complement pathway and became lysed in nonimmune human
serum, whereas the B. afzelii strains did not. However, this
was not due to differences in C3 deposition, that is, both strains
activated the complement system. Kochi et al. also observed that
B. burgdorferi s.s. strain 297 was killed by the classical complement pathway in the presence of antibody but not via the alternative pathway (11). Our results indicate that the
preferential activity to bind factor H and FHL-1 and promote C3b
degradation by B. afzelii and s.s. strains explains why they
are not killed by the alternative pathway. So far, our studies have not
shown any evidence for direct control of the classical pathway by
borreliae. No binding of C4bp was observed (data not shown). Patarakul
et al. suggested in their work that effective MAC-mediated lysis of
B. burgdorferi was not achieved because of different C3
acceptor proteins on serum-resistant WT297 and MUT297 strains
(20). As pathogens, borreliae are likely to have multiple
mechanisms to evade complement attack, including multiple acceptors for
factor H and FHL-1 and inhibition of the terminal complement cascade.
On the basis of the present results one could offer an attractive
explanation for some of the basic aspects of B. burgdorferi infection. Antibody production is typically marked in Lyme disease but
is also markedly ineffective, as evidenced by the fact that the immune
system is in many cases incapable of eradicating the bacterium. With
reduced or ineffective MAC formation the efficiency of
antibody-mediated killing of spirochetes would be decreased. The
observed differences in the abilities of the different genospecies to
cleave C3b are consistent with the previously reported (4) differences in serum sensitivities, suggesting that the ability to bind
factor H and FHL-1 and to promote C3b inactivation is protective in
serum and presumably also in the mammalian host. According to Suhonen
et al. phagocytosis of B. burgdorferi s.l. is mostly
complement mediated (30). The efficacy of phagocytosis of
different borrelia genospecies correlated inversely, we observed, with
the abilities of different genospecies to cleave C3b. The fact that
B. garinii strains are more susceptible to complement than
the other strains may be related to their preference for causing
borreliosis in the central nervous system, where the amount of
complement activity is much smaller than in other compartments of the
human body.
In summary, our observations suggest that B. burgdorferi
s.s. and B. afzelii strains can evade complement activation
by promoting factor I-mediated inactivation of C3b and controlling the
amplification of the complement cascade. Complement resistance
associates with an ability to bind soluble complement regulators factor
H and FHL-1. Neutralization of this resistance may prove useful in the prevention and/or treatment of borreliosis.
 |
ACKNOWLEDGMENTS |
We thank The Helsinki Biomedical Graduate School, The Academy of
Finland, The Sigrid Jusélius Foundation, The University of
Helsinki, and The Helsinki University Central Hospital Research Funds
for funding.
We thank Miikka Peltomaa for coordinating the collection of ticks in
the Helsinki area, Jens Hellwage and Peter Zipfel for FHL-1, and Anna
Blom for C4bp.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University of
Helsinki, Haartman Institute, P.O. Box 21, Haartmaninkatu 3, FIN-00014 University of Helsinki, Finland. Phone: 358-9-1912 6758. Fax: 358-9-1912 6382. E-mail: meri{at}helsinki.fi.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Anthonissen, F. M.,
M. De Kesel,
P. P. Hoet, and G. H. Bigaignon.
1994.
Evidence for the involvement of different genospecies of Borrelia in the clinical outcome of Lyme disease in Belgium.
Res. Microbiol.
145:327-331[Medline].
|
| 2.
|
Assous, V. M.,
D. Postic,
G. Paul,
P. Nevot, and G. Baranton.
1993.
Western blot analysis of sera from Lyme borreliosis patients according to the genomic species of the Borrelia strains used as antigens.
Eur. J. Clin. Microbiol. Infect. Dis.
12:261-268[CrossRef][Medline].
|
| 3.
|
Baranton, G.,
D. Postic,
I. Saint Girons,
P. Boerlin,
J. C. Piffaretti,
M. Assous, and P. A. Grimont.
1992.
Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.
Int. J. Syst. Bacteriol.
42:378-383[Abstract/Free Full Text].
|
| 4.
|
Breitner-Ruddock, S.,
R. Würzner,
J. Schulze, and V. Brade.
1997.
Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi.
Med. Microbiol. Immunol.
185:253-260[CrossRef][Medline].
|
| 5.
|
Fraser, C. M.,
S. Casjens,
W. M. Huang,
G. G. Sutton,
R. Clayton,
R. Lathigra,
O. White,
K. A. Ketchum,
R. Dodson,
E. K. Hickey,
M. Gwinn,
B. Dougherty,
J. F. Tomb,
R. D. Fleischmann,
D. Richardson,
J. Peterson,
A. R. Kerlavage,
J. Quackenbush,
S. Salzberg,
M. Hanson,
R. van Vugt,
N. Palmer,
M. D. Adams,
J. Gocayne,
J. C. Venter, et al.
1997.
Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi.
Nature
390:580-586[CrossRef][Medline].
|
| 6.
|
Hellwage, J.,
S. Kuhn, and P. F. Zipfel.
1997.
The human complement regulatory factor-H-like protein 1, which represents a truncated form of factor H, displays cell-attachment activity.
Biochem. J.
326:321-327.
|
| 7.
|
Hellwage, J.,
T. Meri,
T. Heikkila,
A. Alitalo,
J. Panelius,
P. Lahdenne,
I. J. Seppala, and S. Meri.
2001.
The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi.
J. Biol. Chem.
276:8427-8435[Abstract/Free Full Text].
|
| 8.
|
Horstmann, R. D.,
H. J. Sievertsen,
J. Knobloch, and V. A. Fischetti.
1988.
Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.
Proc. Natl. Acad. Sci. USA
85:1657-1661[Abstract/Free Full Text].
|
| 9.
|
Janulczyk, R.,
F. Iannelli,
A. G. Sjoholm,
G. Pozzi, and L. Bjorck.
2000.
Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function.
J. Biol. Chem.
275:37257-37263[Abstract/Free Full Text].
|
| 10.
|
Jokiranta, S.,
J. Hellwage,
V. Koistinen,
P. F. Zipfel, and S. Meri.
2000.
Each of the three binding sites on complement factor H interacts with a distinct site on C3b.
J. Biol. Chem.
275:27657-27662[Abstract/Free Full Text].
|
| 11.
|
Kochi, S. K.,
R. C. Johnson, and A. P. Dalmasso.
1991.
Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.
J. Immunol.
146:3964-3970[Abstract].
|
| 12.
|
Koistinen, V.
1991.
Effect of complement-protein-C3b density on the binding of complement factor H to surface-bound C3b.
Biochem. J.
280:255-259.
|
| 13.
|
Koistinen, V.,
S. Wessberg, and J. Leikola.
1989.
Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
Complement Inflamm.
6:270-280[Medline].
|
| 14.
|
Kotwal, G. J.
2000.
Poxviral mimicry of complement and chemokine system components: what's the end game?
Immunol. Today
21:242-248[CrossRef][Medline].
|
| 15.
|
Kotwal, G. J.,
S. N. Isaacs,
R. McKenzie,
M. M. Frank, and B. Moss.
1990.
Inhibition of the complement cascade by the major secretory protein of vaccinia virus.
Science
250:827-830[Abstract/Free Full Text].
|
| 16.
|
Lubinski, J.,
L. Wang,
D. Mastellos,
A. Sahu,
J. D. Lambris, and H. M. Friedman.
1999.
In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
J. Exp. Med.
190:1637-1646[Abstract/Free Full Text].
|
| 17.
|
McKenzie, R.,
G. J. Kotwal,
B. Moss,
C. H. Hammer, and M. M. Frank.
1992.
Regulation of complement activity by vaccinia virus complement-control protein.
J. Infect. Dis.
166:1245-1250[Medline].
|
| 18.
|
Meri, S., and M. K. Pangburn.
1990.
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.
Proc. Natl. Acad. Sci. USA
87:3982-3986[Abstract/Free Full Text].
|
| 19.
|
Morgan, B. P., and S. Meri.
1994.
Membrane proteins that protect against complement lysis.
Springer Semin. Immunopathol.
15:369-396[CrossRef][Medline].
|
| 20.
|
Patarakul, K.,
M. F. Cole, and C. A. Hughes.
1999.
Complement resistance in Borrelia burgdorferi strain 297: outer membrane proteins prevent MAC formation at lysis susceptible sites.
Microb. Pathog.
27:25-41[CrossRef][Medline].
|
| 21.
|
Radolf, J. D.,
M. S. Goldberg,
K. Bourell,
S. I. Baker,
J. D. Jones, and M. V. Norgard.
1995.
Characterization of outer membranes isolated from Borrelia burgdorferi, the Lyme disease spirochete.
Infect. Immun.
63:2154-2163[Abstract].
|
| 22.
|
Ram, S.,
D. P. McQuillen,
S. Gulati,
C. Elkins,
M. K. Pangburn, and P. A. Rice.
1998.
Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae.
J. Exp. Med.
188:671-680[Abstract/Free Full Text].
|
| 23.
|
Ram, S.,
A. K. Sharma,
S. D. Simpson,
S. Gulati,
D. P. McQuillen,
M. K. Pangburn, and P. A. Rice.
1998.
A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae.
J. Exp. Med.
187:743-752[Abstract/Free Full Text].
|
| 24.
|
Rautemaa, R., and S. Meri.
1999.
Complement-resistance mechanisms of bacteria.
Microbes Infect.
1:785-794[CrossRef][Medline].
|
| 25.
|
Ribeiro, J. M.
1987.
Ixodes dammini: salivary anti-complement activity.
Exp. Parasitol.
64:347-353[CrossRef][Medline].
|
| 26.
|
Salacinski, P. R.,
C. McLean,
J. E. Sykes,
V. V. Clement-Jones, and P. J. Lowry.
1981.
Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha, 6 alpha-diphenyl glycoluril (Iodogen).
Anal. Biochem.
117:136-146[CrossRef][Medline].
|
| 27.
|
Sharma, A. K., and M. K. Pangburn.
1996.
Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis.
Proc. Natl. Acad. Sci. USA
93:10996-11001[Abstract/Free Full Text].
|
| 28.
|
Steere, A. C.
1989.
Lyme disease.
N. Engl. J. Med.
321:586-596[Abstract].
|
| 29.
|
Steere, A. C.
1994.
Lyme disease: a growing threat to urban populations.
Proc. Natl. Acad. Sci. USA
91:2378-2383[Abstract/Free Full Text].
|
| 30.
|
Suhonen, J.,
K. Hartiala,
H. Tuominen-Gustafsson, and M. K. Viljanen.
2000.
Borrelia burgdorferi induced oxidative burst, calcium mobilization, and phagocytosis of human neutrophils are complement dependent.
J. Infect. Dis.
181:195-202[CrossRef][Medline].
|
| 31.
|
Tambourgi, D. V.,
T. L. Kipnis,
W. D. da Silva,
K. A. Joiner,
A. Sher,
S. Heath,
B. F. Hall, and G. B. Ogden.
1993.
A partial cDNA clone of trypomastigote decay-accelerating factor (T-DAF), a developmentally regulated complement inhibitor of Trypanosoma cruzi, has genetic and functional similarities to the human complement inhibitor DAF.
Infect. Immun.
61:3656-3663[Abstract/Free Full Text].
|
| 32.
|
van Dam, A. P.,
H. Kuiper,
K. Vos,
A. Widjojokusumo,
B. M. de Jongh,
L. Spanjaard,
A. C. Ramselaar,
M. D. Kramer, and J. Dankert.
1993.
Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis.
Clin. Infect. Dis.
17:708-717[Medline].
|
Infection and Immunity, June 2001, p. 3685-3691, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3685-3691.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kenedy, M. R., Vuppala, S. R., Siegel, C., Kraiczy, P., Akins, D. R.
(2009). CspA-Mediated Binding of Human Factor H Inhibits Complement Deposition and Confers Serum Resistance in Borrelia burgdorferi. Infect. Immun.
77: 2773-2782
[Abstract]
[Full Text]
-
Siegel, C., Schreiber, J., Haupt, K., Skerka, C., Brade, V., Simon, M. M., Stevenson, B., Wallich, R., Zipfel, P. F., Kraiczy, P.
(2008). Deciphering the Ligand-binding Sites in the Borrelia burgdorferi Complement Regulator-acquiring Surface Protein 2 Required for Interactions with the Human Immune Regulators Factor H and Factor H-like Protein 1. J. Biol. Chem.
283: 34855-34863
[Abstract]
[Full Text]
-
Hovis, K. M., Freedman, J. C., Zhang, H., Forbes, J. L., Marconi, R. T.
(2008). Identification of an Antiparallel Coiled-Coil/Loop Domain Required for Ligand Binding by the Borrelia hermsii FhbA Protein: Additional Evidence for the Role of FhbA in the Host-Pathogen Interaction. Infect. Immun.
76: 2113-2122
[Abstract]
[Full Text]
-
Kraiczy, P., Seling, A., Brissette, C. A., Rossmann, E., Hunfeld, K.-P., Bykowski, T., Burns, L. H., Troese, M. J., Cooley, A. E., Miller, J. C., Brade, V., Wallich, R., Casjens, S., Stevenson, B.
(2008). Borrelia burgdorferi Complement Regulator-Acquiring Surface Protein 2 (CspZ) as a Serological Marker of Human Lyme Disease. CVI
15: 484-491
[Abstract]
[Full Text]
-
Behnsen, J., Hartmann, A., Schmaler, J., Gehrke, A., Brakhage, A. A., Zipfel, P. F.
(2008). The Opportunistic Human Pathogenic Fungus Aspergillus fumigatus Evades the Host Complement System. Infect. Immun.
76: 820-827
[Abstract]
[Full Text]
-
Poltermann, S., Kunert, A., von der Heide, M., Eck, R., Hartmann, A., Zipfel, P. F.
(2007). Gpm1p Is a Factor H-, FHL-1-, and Plasminogen-binding Surface Protein of Candida albicans. J. Biol. Chem.
282: 37537-37544
[Abstract]
[Full Text]
-
Rogers, E. A., Marconi, R. T.
(2007). Delineation of Species-Specific Binding Properties of the CspZ Protein (BBH06) of Lyme Disease Spirochetes: Evidence for New Contributions to the Pathogenesis of Borrelia spp.. Infect. Immun.
75: 5272-5281
[Abstract]
[Full Text]
-
Herzberger, P., Siegel, C., Skerka, C., Fingerle, V., Schulte-Spechtel, U., van Dam, A., Wilske, B., Brade, V., Zipfel, P. F., Wallich, R., Kraiczy, P.
(2007). Human Pathogenic Borrelia spielmanii sp. nov. Resists Complement-Mediated Killing by Direct Binding of Immune Regulators Factor H and Factor H-Like Protein 1. Infect. Immun.
75: 4817-4825
[Abstract]
[Full Text]
-
Bykowski, T., Woodman, M. E., Cooley, A. E., Brissette, C. A., Brade, V., Wallich, R., Kraiczy, P., Stevenson, B.
(2007). Coordinated Expression of Borrelia burgdorferi Complement Regulator-Acquiring Surface Proteins during the Lyme Disease Spirochete's Mammal-Tick Infection Cycle. Infect. Immun.
75: 4227-4236
[Abstract]
[Full Text]
-
Woodman, M. E., Cooley, A. E., Miller, J. C., Lazarus, J. J., Tucker, K., Bykowski, T., Botto, M., Hellwage, J., Wooten, R. M., Stevenson, B.
(2007). Borrelia burgdorferi Binding of Host Complement Regulator Factor H Is Not Required for Efficient Mammalian Infection. Infect. Immun.
75: 3131-3139
[Abstract]
[Full Text]
-
Hammerschmidt, S., Agarwal, V., Kunert, A., Haelbich, S., Skerka, C., Zipfel, P. F.
(2007). The Host Immune Regulator Factor H Interacts via Two Contact Sites with the PspC Protein of Streptococcus pneumoniae and Mediates Adhesion to Host Epithelial Cells. J. Immunol.
178: 5848-5858
[Abstract]
[Full Text]
-
Jacobson, A. C., Ma, Y., Zachary, J. F., Weis, J. J., Weis, J. H.
(2007). Mice Lacking CD21 and CD35 Proteins Mount Effective Immune Responses against Borrelia burgdorferi Infection. Infect. Immun.
75: 2075-2078
[Abstract]
[Full Text]
-
McDowell, J. V., Frederick, J., Stamm, L., Marconi, R. T.
(2007). Identification of the Gene Encoding the FhbB Protein of Treponema denticola, a Highly Unique Factor H-Like Protein 1 Binding Protein. Infect. Immun.
75: 1050-1054
[Abstract]
[Full Text]
-
Rossmann, E., Kitiratschky, V., Hofmann, H., Kraiczy, P., Simon, M. M., Wallich, R.
(2006). Borrelia burgdorferi Complement Regulator-Acquiring Surface Protein 1 of the Lyme Disease Spirochetes Is Expressed in Humans and Induces Antibody Responses Restricted to Nondenatured Structural Determinants. Infect. Immun.
74: 7024-7028
[Abstract]
[Full Text]
-
Meri, T., Cutler, S. J., Blom, A. M., Meri, S., Jokiranta, T. S.
(2006). Relapsing Fever Spirochetes Borrelia recurrentis and B. duttonii Acquire Complement Regulators C4b-Binding Protein and Factor H. Infect. Immun.
74: 4157-4163
[Abstract]
[Full Text]
-
Verma, A., Hellwage, J., Artiushin, S., Zipfel, P. F., Kraiczy, P., Timoney, J. F., Stevenson, B.
(2006). LfhA, a Novel Factor H-Binding Protein of Leptospira interrogans.. Infect. Immun.
74: 2659-2666
[Abstract]
[Full Text]
-
Hovis, K. M., Tran, E., Sundy, C. M., Buckles, E., McDowell, J. V., Marconi, R. T.
(2006). Selective Binding of Borrelia burgdorferi OspE Paralogs to Factor H and Serum Proteins from Diverse Animals: Possible Expansion of the Role of OspE in Lyme Disease Pathogenesis. Infect. Immun.
74: 1967-1972
[Abstract]
[Full Text]
-
Zhang, H., Marconi, R. T.
(2005). Demonstration of Cotranscription and 1-Methyl-3-Nitroso-Nitroguanidine Induction of a 30-Gene Operon of Borrelia burgdorferi: Evidence that the 32-Kilobase Circular Plasmids Are Prophages. J. Bacteriol.
187: 7985-7995
[Abstract]
[Full Text]
-
McDowell, J. V., Lankford, J., Stamm, L., Sadlon, T., Gordon, D. L., Marconi, R. T.
(2005). Demonstration of Factor H-Like Protein 1 Binding to Treponema denticola, a Pathogen Associated with Periodontal Disease in Humans. Infect. Immun.
73: 7126-7132
[Abstract]
[Full Text]
-
von Lackum, K., Miller, J. C., Bykowski, T., Riley, S. P., Woodman, M. E., Brade, V., Kraiczy, P., Stevenson, B., Wallich, R.
(2005). Borrelia burgdorferi Regulates Expression of Complement Regulator-Acquiring Surface Protein 1 during the Mammal-Tick Infection Cycle. Infect. Immun.
73: 7398-7405
[Abstract]
[Full Text]
-
Brooks, C. S., Vuppala, S. R., Jett, A. M., Alitalo, A., Meri, S., Akins, D. R.
(2005). Complement Regulator-Acquiring Surface Protein 1 Imparts Resistance to Human Serum in Borrelia burgdorferi. J. Immunol.
175: 3299-3308
[Abstract]
[Full Text]
-
Wallich, R., Pattathu, J., Kitiratschky, V., Brenner, C., Zipfel, P. F., Brade, V., Simon, M. M., Kraiczy, P.
(2005). Identification and Functional Characterization of Complement Regulator-Acquiring Surface Protein 1 of the Lyme Disease Spirochetes Borrelia afzelii and Borrelia garinii. Infect. Immun.
73: 2351-2359
[Abstract]
[Full Text]
-
McDowell, J. V., Harlin, M. E., Rogers, E. A., Marconi, R. T.
(2005). Putative Coiled-Coil Structural Elements of the BBA68 Protein of Lyme Disease Spirochetes Are Required for Formation of Its Factor H Binding Site. J. Bacteriol.
187: 1317-1323
[Abstract]
[Full Text]
-
Nunn, M. A., Sharma, A., Paesen, G. C., Adamson, S., Lissina, O., Willis, A. C., Nuttall, P. A.
(2005). Complement Inhibitor of C5 Activation from the Soft Tick Ornithodoros moubata. J. Immunol.
174: 2084-2091
[Abstract]
[Full Text]
-
McDowell, J. V., Wolfgang, J., Senty, L., Sundy, C. M., Noto, M. J., Marconi, R. T.
(2004). Demonstration of the Involvement of Outer Surface Protein E Coiled Coil Structural Domains and Higher Order Structural Elements in the Binding of Infection-Induced Antibody and the Complement-Regulatory Protein, Factor H. J. Immunol.
173: 7471-7480
[Abstract]
[Full Text]
-
Simmons, W. L., Denison, A. M., Dybvig, K.
(2004). Resistance of Mycoplasma pulmonis to Complement Lysis Is Dependent on the Number of Vsa Tandem Repeats: Shield Hypothesis. Infect. Immun.
72: 6846-6851
[Abstract]
[Full Text]
-
Dave, S., Carmicle, S., Hammerschmidt, S., Pangburn, M. K., McDaniel, L. S.
(2004). Dual Roles of PspC, a Surface Protein of Streptococcus pneumoniae, in Binding Human Secretory IgA and Factor H. J. Immunol.
173: 471-477
[Abstract]
[Full Text]
-
Alitalo, A., Meri, T., Chen, T., Lankinen, H., Cheng, Z.-Z., Jokiranta, T. S., Seppala, I. J. T., Lahdenne, P., Hefty, P. S., Akins, D. R., Meri, S.
(2004). Lysine-Dependent Multipoint Binding of the Borrelia burgdorferi Virulence Factor Outer Surface Protein E to the C Terminus of Factor H. J. Immunol.
172: 6195-6201
[Abstract]
[Full Text]
-
Hovis, K. M., McDowell, J. V., Griffin, L., Marconi, R. T.
(2004). Identification and Characterization of a Linear-Plasmid-Encoded Factor H-Binding Protein (FhbA) of the Relapsing Fever Spirochete Borrelia hermsii. J. Bacteriol.
186: 2612-2618
[Abstract]
[Full Text]
-
Babb, K., McAlister, J. D., Miller, J. C., Stevenson, B.
(2004). Molecular Characterization of Borrelia burgdorferi erp Promoter/Operator Elements. J. Bacteriol.
186: 2745-2756
[Abstract]
[Full Text]
-
Kraiczy, P., Hellwage, J., Skerka, C., Becker, H., Kirschfink, M., Simon, M. M., Brade, V., Zipfel, P. F., Wallich, R.
(2004). Complement Resistance of Borrelia burgdorferi Correlates with the Expression of BbCRASP-1, a Novel Linear Plasmid-encoded Surface Protein That Interacts with Human Factor H and FHL-1 and Is Unrelated to Erp Proteins. J. Biol. Chem.
279: 2421-2429
[Abstract]
[Full Text]
-
Miller, J. C., von Lackum, K., Babb, K., McAlister, J. D., Stevenson, B.
(2003). Temporal Analysis of Borrelia burgdorferi Erp Protein Expression throughout the Mammal-Tick Infectious Cycle. Infect. Immun.
71: 6943-6952
[Abstract]
[Full Text]
-
Simmons, W. L., Dybvig, K.
(2003). The Vsa Proteins Modulate Susceptibility of Mycoplasma pulmonis to Complement Killing, Hemadsorption, and Adherence to Polystyrene. Infect. Immun.
71: 5733-5738
[Abstract]
[Full Text]
-
Lawrenz, M. B., Wooten, R. M., Zachary, J. F., Drouin, S. M., Weis, J. J., Wetsel, R. A., Norris, S. J.
(2003). Effect of Complement Component C3 Deficiency on Experimental Lyme Borreliosis in Mice. Infect. Immun.
71: 4432-4440
[Abstract]
[Full Text]
-
McDowell, J. V., Tran, E., Hamilton, D., Wolfgang, J., Miller, K., Marconi, R. T.
(2003). Analysis of the Ability of Spirochete Species Associated with Relapsing Fever, Avian Borreliosis, and Epizootic Bovine Abortion To Bind Factor H and Cleave C3b. J. Clin. Microbiol.
41: 3905-3910
[Abstract]
[Full Text]
-
Iyer, R., Kalu, O., Purser, J., Norris, S., Stevenson, B., Schwartz, I.
(2003). Linear and Circular Plasmid Content in Borrelia burgdorferi Clinical Isolates. Infect. Immun.
71: 3699-3706
[Abstract]
[Full Text]
-
Metts, M. S., McDowell, J. V., Theisen, M., Hansen, P. R., Marconi, R. T.
(2003). Analysis of the OspE Determinants Involved in Binding of Factor H and OspE-Targeting Antibodies Elicited during Borreliaburgdorferi Infection in Mice. Infect. Immun.
71: 3587-3596
[Abstract]
[Full Text]
-
McDowell, J. V., Wolfgang, J., Tran, E., Metts, M. S., Hamilton, D., Marconi, R. T.
(2003). Comprehensive Analysis of the Factor H Binding Capabilities of Borrelia Species Associated with Lyme Disease: Delineation of Two Distinct Classes of Factor H Binding Proteins. Infect. Immun.
71: 3597-3602
[Abstract]
[Full Text]
-
Pausa, M., Pellis, V., Cinco, M., Giulianini, P. G., Presani, G., Perticarari, S., Murgia, R., Tedesco, F.
(2003). Serum-Resistant Strains of Borrelia burgdorferi Evade Complement-Mediated Killing by Expressing a CD59-Like Complement Inhibitory Molecule. J. Immunol.
170: 3214-3222
[Abstract]
[Full Text]
-
Rathinavelu, S., Broadwater, A., de Silva, A. M.
(2003). Does Host Complement Kill Borrelia burgdorferi within Ticks?. Infect. Immun.
71: 822-829
[Abstract]
[Full Text]
-
Alitalo, A., Meri, T., Lankinen, H., Seppala, I., Lahdenne, P., Hefty, P. S., Akins, D., Meri, S.
(2002). Complement Inhibitor Factor H Binding to Lyme Disease Spirochetes Is Mediated by Inducible Expression of Multiple Plasmid-Encoded Outer Surface Protein E Paralogs. J. Immunol.
169: 3847-3853
[Abstract]
[Full Text]
-
Meri, T., Hartmann, A., Lenk, D., Eck, R., Wurzner, R., Hellwage, J., Meri, S., Zipfel, P. F.
(2002). The Yeast Candida albicans Binds Complement Regulators Factor H and FHL-1. Infect. Immun.
70: 5185-5192
[Abstract]
[Full Text]
-
Jarva, H., Janulczyk, R., Hellwage, J., Zipfel, P. F., Bjorck, L., Meri, S.
(2002). Streptococcus pneumoniae Evades Complement Attack and Opsonophagocytosis by Expressing the pspC Locus-Encoded Hic Protein That Binds to Short Consensus Repeats 8-11 of Factor H. J. Immunol.
168: 1886-1894
[Abstract]
[Full Text]
-
Stevenson, B., El-Hage, N., Hines, M. A., Miller, J. C., Babb, K.
(2002). Differential Binding of Host Complement Inhibitor Factor H by Borrelia burgdorferi Erp Surface Proteins: a Possible Mechanism Underlying the Expansive Host Range of Lyme Disease Spirochetes. Infect. Immun.
70: 491-497
[Abstract]
[Full Text]